Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States

Lael Cragin, Feng Pan, Siyang Peng, Jonathan Mark Zenilman, Julia Green, Cynthia Doucet, Donald Chalfin, Greg De Lissovoy

Research output: Contribution to journalArticle

Abstract

Purpose: The US Food and Drug Administration recently approved the first 4th-generation HIV test. This study evaluated the cost-effectiveness of the 4th-generation assay versus a 3rd-generation test in screening for HIV infections in the United States. Methods: An exploratory microsimulation model was developed that follows hypothetical individuals and simulates the course of HIV/AIDS, treatment with highly active antiretroviral therapy, and transmissions. Results: With a 1% HIV prevalence, screening 1.5 million individuals with the 4th-versus 3rd-generation assay resulted in detection of 266 additional HIV cases at an incremental cost per additional HIV case detected of $63,763, an additional 489 life years and 395 quality-adjusted life years (QALYs), and 26 HIV transmissions prevented. Although lifetime costs were increased by $33.6 million, the incremental cost/QALY gained was $85,206. The 4th-generation test was more cost-effective in high incidence settings. The number needed to screen to detect one additional HIV case was 5,635. Conclusions: Screening using the 4th-generation assay may be cost-effective for HIV detection in appropriate settings, resulting in increased case identification, fewer transmissions, extended life, and increased quality of life. With early and accurate detection, this 4th-generation test may provide a suitable alternative to current 3rd-generation tests.

Original languageEnglish (US)
Pages (from-to)11-22
Number of pages12
JournalHIV Clinical Trials
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Virus Diseases
Immunoassay
Cost-Benefit Analysis
HIV
Antigens
Antibodies
Costs and Cost Analysis
Quality-Adjusted Life Years
Quality of Life
Highly Active Antiretroviral Therapy
United States Food and Drug Administration
HIV-1
Acquired Immunodeficiency Syndrome
Incidence

Keywords

  • cost-effectiveness
  • HIV infection
  • screening
  • testing

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States. / Cragin, Lael; Pan, Feng; Peng, Siyang; Zenilman, Jonathan Mark; Green, Julia; Doucet, Cynthia; Chalfin, Donald; De Lissovoy, Greg.

In: HIV Clinical Trials, Vol. 13, No. 1, 01.01.2012, p. 11-22.

Research output: Contribution to journalArticle

Cragin, Lael ; Pan, Feng ; Peng, Siyang ; Zenilman, Jonathan Mark ; Green, Julia ; Doucet, Cynthia ; Chalfin, Donald ; De Lissovoy, Greg. / Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States. In: HIV Clinical Trials. 2012 ; Vol. 13, No. 1. pp. 11-22.
@article{dcec1e681cb041a89d89238e15c0115c,
title = "Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States",
abstract = "Purpose: The US Food and Drug Administration recently approved the first 4th-generation HIV test. This study evaluated the cost-effectiveness of the 4th-generation assay versus a 3rd-generation test in screening for HIV infections in the United States. Methods: An exploratory microsimulation model was developed that follows hypothetical individuals and simulates the course of HIV/AIDS, treatment with highly active antiretroviral therapy, and transmissions. Results: With a 1{\%} HIV prevalence, screening 1.5 million individuals with the 4th-versus 3rd-generation assay resulted in detection of 266 additional HIV cases at an incremental cost per additional HIV case detected of $63,763, an additional 489 life years and 395 quality-adjusted life years (QALYs), and 26 HIV transmissions prevented. Although lifetime costs were increased by $33.6 million, the incremental cost/QALY gained was $85,206. The 4th-generation test was more cost-effective in high incidence settings. The number needed to screen to detect one additional HIV case was 5,635. Conclusions: Screening using the 4th-generation assay may be cost-effective for HIV detection in appropriate settings, resulting in increased case identification, fewer transmissions, extended life, and increased quality of life. With early and accurate detection, this 4th-generation test may provide a suitable alternative to current 3rd-generation tests.",
keywords = "cost-effectiveness, HIV infection, screening, testing",
author = "Lael Cragin and Feng Pan and Siyang Peng and Zenilman, {Jonathan Mark} and Julia Green and Cynthia Doucet and Donald Chalfin and {De Lissovoy}, Greg",
year = "2012",
month = "1",
day = "1",
doi = "10.1310/hct1301-11",
language = "English (US)",
volume = "13",
pages = "11--22",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States

AU - Cragin, Lael

AU - Pan, Feng

AU - Peng, Siyang

AU - Zenilman, Jonathan Mark

AU - Green, Julia

AU - Doucet, Cynthia

AU - Chalfin, Donald

AU - De Lissovoy, Greg

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: The US Food and Drug Administration recently approved the first 4th-generation HIV test. This study evaluated the cost-effectiveness of the 4th-generation assay versus a 3rd-generation test in screening for HIV infections in the United States. Methods: An exploratory microsimulation model was developed that follows hypothetical individuals and simulates the course of HIV/AIDS, treatment with highly active antiretroviral therapy, and transmissions. Results: With a 1% HIV prevalence, screening 1.5 million individuals with the 4th-versus 3rd-generation assay resulted in detection of 266 additional HIV cases at an incremental cost per additional HIV case detected of $63,763, an additional 489 life years and 395 quality-adjusted life years (QALYs), and 26 HIV transmissions prevented. Although lifetime costs were increased by $33.6 million, the incremental cost/QALY gained was $85,206. The 4th-generation test was more cost-effective in high incidence settings. The number needed to screen to detect one additional HIV case was 5,635. Conclusions: Screening using the 4th-generation assay may be cost-effective for HIV detection in appropriate settings, resulting in increased case identification, fewer transmissions, extended life, and increased quality of life. With early and accurate detection, this 4th-generation test may provide a suitable alternative to current 3rd-generation tests.

AB - Purpose: The US Food and Drug Administration recently approved the first 4th-generation HIV test. This study evaluated the cost-effectiveness of the 4th-generation assay versus a 3rd-generation test in screening for HIV infections in the United States. Methods: An exploratory microsimulation model was developed that follows hypothetical individuals and simulates the course of HIV/AIDS, treatment with highly active antiretroviral therapy, and transmissions. Results: With a 1% HIV prevalence, screening 1.5 million individuals with the 4th-versus 3rd-generation assay resulted in detection of 266 additional HIV cases at an incremental cost per additional HIV case detected of $63,763, an additional 489 life years and 395 quality-adjusted life years (QALYs), and 26 HIV transmissions prevented. Although lifetime costs were increased by $33.6 million, the incremental cost/QALY gained was $85,206. The 4th-generation test was more cost-effective in high incidence settings. The number needed to screen to detect one additional HIV case was 5,635. Conclusions: Screening using the 4th-generation assay may be cost-effective for HIV detection in appropriate settings, resulting in increased case identification, fewer transmissions, extended life, and increased quality of life. With early and accurate detection, this 4th-generation test may provide a suitable alternative to current 3rd-generation tests.

KW - cost-effectiveness

KW - HIV infection

KW - screening

KW - testing

UR - http://www.scopus.com/inward/record.url?scp=84858195640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858195640&partnerID=8YFLogxK

U2 - 10.1310/hct1301-11

DO - 10.1310/hct1301-11

M3 - Article

C2 - 22306584

AN - SCOPUS:84858195640

VL - 13

SP - 11

EP - 22

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 1

ER -